BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm

BetterLife secures $100 million and hires LifeSci Advisors for IR at $26,750/month.

What the company is saying

BetterLife Pharma Inc. (CSE:BETR, OTCQB:BETRF, FSE:NPAU) announces it has retained LifeSci Advisors to manage investor relations and corporate communications. The company highlights that LifeSci will receive a monthly fee of $24,250 for IR services and $2,500 for media programs, with no equity-based compensation. The engagement is for an initial 12-month term, automatically renewing unless terminated with 60 days’ notice. BetterLife emphasizes its recent $100 million financing led by Deep Track Capital, with co-investments from several major healthcare institutional investors. The company frames the engagement as timely, citing 'strong interest from the investment community' as it advances its lead drug candidate, BETR-001, toward an IND submission in Q1 2027 and clinical development later that year. The tone is confident, stressing a strengthened balance sheet and the addition of renowned headache experts Peter Goadsby and Richard Lipton as Scientific Advisory Board Co-Chairs. The company is careful to clarify that BETR-001 is investigational, unapproved, and not yet validated for efficacy by regulators.

What the data suggests

The company has completed a $100 million financing, led by Deep Track Capital and supported by multiple institutional investors, which materially strengthens its balance sheet. LifeSci Advisors will receive a total of $26,750 per month ($24,250 for IR, $2,500 for media), with the contract running for at least 12 months and automatically renewing unless notice is given. No equity or options are involved in the IR compensation, and LifeSci holds no securities in the company. The timeline for BETR-001 is long-dated, with IND submission targeted for Q1 2027 and clinical development to begin later that year; no clinical or regulatory milestones have yet been achieved. The company holds a granted U.S. composition-of-matter patent for BETR-001, but the drug remains investigational and unapproved, with no efficacy confirmed by research or regulatory review. The announcement provides full transparency on the IR contract and recent financing but does not disclose operational, clinical, or revenue figures. The involvement of high-profile institutional investors and scientific advisors signals external validation, but does not guarantee future success or follow-on investment.

Analysis

The announcement is upbeat, highlighting a major USD$100 million financing and the engagement of a high-profile investor relations firm, which are both realised and well-supported facts. However, the advancement of BETR-001 is entirely forward-looking: the company is only targeting IND submission in Q1 2027, with clinical development to follow, meaning any clinical or commercial benefits are at least 1-2 years away. No clinical data, regulatory filings, or operational milestones are disclosed, and the company explicitly states that BETR-001 is investigational and unapproved, with no efficacy confirmed. The large capital raise is positive, but the absence of near-term catalysts or measurable progress on the drug program means the narrative leans on future potential rather than realised value. The tone is further inflated by references to 'strong interest from the investment community' without supporting evidence. Overall, the gap between narrative and evidence is moderate: the financing is real, but the core business progress is aspirational and long-dated.

Risk flags

• ●The core asset, BETR-001, is still preclinical with IND submission not targeted until Q1 2027, meaning there is no near-term path to revenue or clinical validation; this exposes investors to multi-year development and regulatory risk.
• ●The $100 million financing, while strengthening the balance sheet, does not guarantee successful clinical outcomes or future funding; institutional participation is a positive signal but does not obligate further support.
• ●The company is increasing its fixed monthly costs by $26,750 for investor relations and media, which, while modest relative to the financing, adds to cash burn in the absence of operating revenue.
• ●All claims regarding BETR-001’s potential are forward-looking and unsubstantiated by clinical or regulatory data, with the company itself cautioning that efficacy has not been confirmed and approvals are not assured.

Bottom line

BetterLife Pharma has secured $100 million in new funding from a syndicate of institutional healthcare investors, providing a strong financial base for its next phase. The company is committing $26,750 per month to LifeSci Advisors for investor relations and media, with transparent contract terms and no equity compensation. While the addition of prominent scientific advisors and institutional investors lends credibility, the company’s lead asset, BETR-001, is still at least a year away from IND submission and clinical development, with no efficacy or regulatory validation to date. All core business value remains forward-looking and contingent on future clinical progress. Investors should recognize that while the balance sheet is now well-capitalized, the timeline to any commercial or clinical milestone is long, and the risk of non-approval or clinical failure remains high. The most important takeaway is that this is a capital-raising and profile-building announcement, not a clinical or commercial breakthrough.

Announcement summary

(CSE:BETR, OTCQB:BETRF, FSE:NPAU) BetterLife Pharma Inc., a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, has retained LifeSci Advisors to support its investor relations and corporate communications activities. The engagement of LifeSci Advisors is pursuant to the policies of the Canadian Securities Exchange. BetterLife is advancing BETR-001, a novel, non-hallucinogenic neuroplastogen, as a potential preventive treatment for chronic migraine and cluster headache. The company is targeting submission of an Investigational New Drug (IND) application in the first quarter of 2027 and plans to initiate clinical development during the year. BetterLife recently strengthened its Scientific Advisory Board with the appointments of Professors Peter Goadsby and Richard Lipton as Co-Chairs. The company recently completed a USD$100 million financing led by Deep Track Capital, with significant co-investments from Coastlands Capital, Marshall Wace, RA Capital Management, and Perceptive Advisors, and participation from Adage Capital Management, Affinity Asset Advisors, Kalehua Capital, Sphera Fund Management, Squadron Capital Management, Stonepine Capital Management, Woodline Partners LP, and other healthcare specialized institutional investors. LifeSci Advisors will be paid monthly fees of USD$24,250 for investor relations services and USD$2,500 for key media programs, such as media outreach and social media development. LifeSci Advisors will not receive any equity-based compensation. The engagement is for an initial term of twelve (12) months, automatically renewed for successive twelve (12) month periods unless sixty (60) day prior written notice is provided by either party. Services by LifeSci will include digital marketing, email newsletters, social media, conference coordination, and direct investor outreach. Ahmad Doroudian, PhD, Chief Executive Officer of BetterLife, stated that the company is seeing strong interest from the investment community as it advances BETR-001 toward the clinic and prepares for important development milestones in 2027. LifeSci Advisors acts at arms-length to the company and currently holds no common shares or other securities of BetterLife. BETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide (2-Br-LSD) in development for the preventive treatment of chronic cluster headache and chronic migraine. BetterLife holds a granted U.S. composition-of-matter patent covering BETR-001. BETR-001 is an investigational product and has not been approved by any regulatory authority. The company makes no medical, treatment, or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada, or other similar regulatory authorities have not evaluated claims regarding BETR-001 or other programs of the company. The efficacy of such products has not been confirmed by approved research. There is no assurance that BETR-001 or other programs of the company can diagnose, treat, cure, or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the company's performance and operations.

Disagree with this article?